Clinical Trial Detail

NCT ID NCT01633970
Title A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Genentech

Advanced Solid Tumor


Atezolizumab + Carboplatin + Paclitaxel

Atezolizumab + Carboplatin + Pemetrexed Disodium

Atezolizumab + Bevacizumab + Capecitabine

Age Groups: adult

No variant requirements are available.